It does seem odd that the FDA has now had a full w
Post# of 148179
Surely the folks charged with this task don't take weekends off in the middle of a pandemic when there is a potential game-changing therapeutic requesting an Unmet Need EUA (but maybe they don't consider analyzing Phase 2 trial results as being as high a priority).
Therefore, I have to assume there are conversations taking place between CytoDyn and the FDA -- with the FDA seeking clarification, or requesting additional information, or discussing the particulars of the next step -- which could be Phase 3 Registrational, Phase 4 Confirmational, or EUA.
If the outcome is a Phase 4 Confirmational or EUA I would expect we'd know about it immediately.
Alternatively, if it is a Phase 3, maybe Dr.NP is strategically using the four business days the SEC allows before a material disclosure must be made public to allow Mexico or the UK pull the trigger without learning of the FDA's decision.